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Cardiovascular Disease, Neuropathy, and
Retinopathy
ZACHARY T. BLOOMGARDEN, MD
T
his is the sixth of a series of six arti-
cles based on presentations at the
American Diabetes Association Sci-
entiﬁc Sessions held 6–10 June 2008 in
San Francisco, California.
Role of glycemia in
cardiovascular disease
Jacqueline Dekker (Amsterdam, the
Netherlands) discussed the association
between hyperglycemia and cardiovascu-
lar disease (CVD), particularly addressing
A1C measurement in nondiabetic indi-
viduals. A1C, she noted, is considered a
gold-standard measure of chronic glyce-
mia in diabetic patients. In nondiabetic
populations, its implications are some-
what less clear. In a study of 648 appar-
ently healthy individuals, 12% had an
elevated total A1 level (measured in that
study) not explained by measurement er-
ror or glucose intolerance and remaining
inthesamerangeover3.5yearsin90%of
those initially with high and in 68% of
thoseinitiallywithlowbaselinelevels(1).
Therewasnocorrelationwithglucosetol-
erance, with caloric intake, or with phys-
ical activity, but A1 level was associated
withcigaretteuseandwithclinicallyovert
atherosclerosis, leading Dekker to con-
clude that “factors unrelated to glucose
metabolism are the main determinants of
A1” in nondiabetic individuals, perhaps
with bearing on risk of what are consid-
ered complications of diabetes. A subse-
quent study of 3,240 nondiabetic
individuals showed weak correlation of
A1C with fasting and 2-h glucose, choles-
terol, and insulin. Weak but signiﬁcant
correlations were also found with eryth-
rocyte characteristics, and cigarette use
was associated with higher A1C, again
suggesting nonglycemic effects on hemo-
globin glycation (2). In the Islington Dia-
betes Survey, 1,084 participants had
glucose tolerance tests and four different
A1C assays. The 2-h postload glucose ex-
plained 19–41% of the variation in A1C,
depending on the assay, and 26–48% of
the variation was explained by the fasting
glucose, with low and high glycators re-
maining constant over 4 years (3). If 50–
80% is not explained by glycemia, the
implication is, again, that although im-
portant in understanding diabetes, A1C
must be considered cautiously with re-
gardtoimplicationsofmechanisticcauses
of complications of hyperglycemia.
In a study of ﬁve individuals with low
and seven with high A1C, relative to the
2-hglucose,therewasastrongerrelation-
shipbetweenglycatedalbuminandblood
glucose and no differences in insulin,
urea, free fatty acids, vitamin C, or intra-
erythrocyte organic phosphate. Higher
erythrocyte2,3diphosphoglyceratelevels
andhigherintracellularpHwerefoundin
the higher glycators (4). Dekker showed
further evidence from a study of identical
twins that A1C levels are genetically de-
terminedevenintype1diabetes,explain-
ing 62% of the variation in A1C (5).
Potential glucose-independent mecha-
nisms include hemoglobin glycation,
erythrocyte cell membrane permeability
to glucose, erythrocyte survival, and intra-
erythrocyte pH. In the Diabetes Preven-
tion Program, among individuals with
impaired glucose tolerance there were
ethnic group differences in A1C not ex-
plained by glycemic differences, with
blacks having mean A1C levels 0.5%
greaterthanwhiteswithoutadifferencein
glucose tolerance (6).
Therelationshipbetweenhyperglyce-
mia and mortality was best shown in the
European DECODE study, with a step-
wise relationship between 2-h glucose
and mortality from low levels to impaired
glucose tolerance to type 2 diabetes, with
the association less convincing for fasting
glucose (7). A meta-analysis of studies
measuring fasting and 2-h glucose and
A1C suggested that risk was related to all
indicators, with a stronger relationship
forwomenthanformen;afteradjustment
forcardiovascularriskfactors,thehighest
glycemiagrouphad19%greaterriskthan
the lowest (8). In the Rancho Bernardo
study, A1C was a better CVD predictor
than fasting or 2-h glucose (9); in the Fra-
mingham Offspring study CVD risk in-
creased 15% per SD increase in A1C,
independent of fasting glucose and 2-h
glucose (10); in the Epic-Norfolk study,
there was a 1.2- to 1.3-fold increase in
cardiovascular risk for each 1% increase
in A1C (11); and in the Atherosclerosis
Risk in Communities study, A1C was as-
sociated with both stroke and coronary
heart disease risk (12). However, in the
Women’s Health Study myocardial in-
farction, stroke, and revascularization
werenotassociatedwithA1Cafteradjust-
ment for risk factors (13).
In Dekker’s studies in Hoorn in the
Netherlands, baseline examination of
2,848 men and women (aged 50–75
years) between 1989 and 1990 included
glucose tolerance testing, with the corre-
lation coefﬁcients of A1C vs. fasting and
2-h glucose 0.24 and 0.14, respectively,
in individuals with normal glucose toler-
ance, with 16% of this group having A1C
6%. Among 1,675 nondiabetic individ-
uals with A1C measurement, 10 year fol-
low-up showed strong associations of
A1C both with fatal and with nonfatal
CVD, with 1.7- and 3.0-fold increases in
risk per 1% increase in A1C among men
and women, respectively, while neither
fastingnor2-hglucoseshowedsigniﬁcant
effect when other CVD risk factors were
taken into account, leading Dekker to
speculate that the continuous relation-
ship between A1C and CVD is only to a
limited extent due to glycemia. A1C
might rather reﬂect an individual’s vul-
nerability to hyperglycemia. She sug-
gested that glucose tolerance testing
remains important to determine an indi-
vidual’s status, with lifestyle intervention
particularly effective among individuals
with higher diabetes risk (14). She noted
further that glucose is a direct measure of
diabetes, while A1C is indirect and the
time course of the relationship between
increase in A1C and glycemia is not
known. Furthermore, there is no infor-
mationastoeffectivenessofinterventions
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Hertzel Gerstein (Hamilton, ON, Can-
ada) discussed the relationship between
A1C and CVD in individuals with diabetes.
The question of the consequences of dia-
betes should be considered to include eye
(cataract, retina), kidney, nerve, periph-
eral arterial disease, ulcer/amputation,
ischemic heart disease, stroke, cirrhosis,
earlydeath,cognitivedecline,depression,
hip fracture, imbalance and frailty, joint
abnormality, erectile dysfunction, sexual
dysfunction, and infertility. Not all of
these abnormalities, he pointed out, are
related to elevated glucose.
There is certainly a strong relation-
ship between diabetes and CVD. A 2006
meta-analysis of 37 prospective studies
from 1966 to 2005 including 447,064
diabetic patients (45% of whom were
women) found that diabetic men and
women were 2.0 and 3.1 times more
likely to have CVD, respectively, after ad-
justment for other risk factors (15). In a
population-based study from Ontario an-
alyzing 379,003 diabetic and 9,018,082
nondiabetic individuals followed from
1994 to 2000, those with diabetes and
those with history of myocardial infarc-
tion each had doubling of mortality risk;
diabetic individuals developed high risk
of CVD, as deﬁned either by an annual
event rate of 2% or an event rate equiva-
lenttothatassociatedwithpreviousmyo-
cardial infarction, at an age 15 years
younger than that for nondiabetic individ-
uals, whereas diabetic men and women
entered the high-risk category at ages
41–48and48–54years,respectively.Be-
lowage40years,diabeticindividualstyp-
ically did not have a high risk by these
deﬁnitions (16), but one may clearly con-
sider diabetes “a serious disease.”
A1C level does provide additional in-
formation pertaining to risk of complica-
tions of diabetes. In the UK Prospective
Diabetes Study (UKPDS), for every 1%
increase in A1C there was 21% higher
mortality,14%higherfatal/nonfatalmyo-
cardial infarction, 37% higher eye and
kidney end points, 43% higher amputa-
tion, and 16% higher heart failure. A
meta-analysis of prospective epidemio-
logic studies including the UKPDS, ad-
justing for age, smoking, glucose, and
duration, showed 18% higher CVD levels
for every 1% increase in A1C (17). Inter-
estingly, however, there may be a less
steep relationship between A1C and risk
diabetic patients than with in those with-
outdiabetes(18).Why,Gersteinasked,is
there a link between A1C and CVD?
There is clearly a relationship between
glucose and A1C in the general popula-
tion, with potential for a direct adverse
effectofhighglucoseperse.Alternatively,
it may be that higher levels of glucose are
associated with lower levels of insulin se-
cretion or of insulin action, which might
cause CVD—or there may be genetic or
environmental factors that predispose to
both dysglycemia and CVD (19). A ﬁnal
and very important question is whether
A1C lowering reduces CVD. Gerstein re-
viewed data from the UKPDS with a 0.9%
median difference in A1C over 10 years
associated with reduction in microvascu-
lar disease and stated that only with met-
formin was there signiﬁcant evidence of
decreased macrovascular disease, despite
its lesser effect in lowering A1C, suggest-
ing that the method by which glucose is
loweredmightbeimportant.(Subsequent
to the lecture, the UKPDS group pub-
lished 10-year follow-up data, however,
showing that the glycemic intervention
did lead to signiﬁcant reduction in myo-
cardial infarction or mortality (20). Ger-
stein concluded that “lowering A1C with
some therapies in some people may re-
duce CVD,” but cautioned that “we have
to take the data” of the new studies to
modify our understanding and our treat-
ment recommendations. It may be that
earliertreatmentwillbebetterandthat“it
is much easier to halt the process” than to
reverse existing disease.
Vivian Fonseca (New Orleans, LA)
discussed the “myth that insulin treat-
ment is atherogenic,” stating, rather, that
endogenous hyperinsulinemia and the
need for higher doses of exogenous insu-
lin should be considered markers of un-
derlying insulin resistance, which is the
cause of greater levels of atherosclerosis.
Certainly,theDiabetesControlandCom-
plications Trial (DCCT) follow-up of the
intensively treated group showed reduc-
tion in carotid atherosclerosis (21) and
fewer cardiovascular events (22). In the
Diabetes Mellitus, Insulin Glucose Infu-
sion in Acute Myocardial Infarction
(DIGAMI) study, diabetic individuals en-
tering the hospital with myocardial in-
farction beneﬁted from insulin treatment
(23), but neither the DIGAMI 2 study, in
which the standard group had glycemia
similar to that in the intervention group
(24), nor the CREATE-ECLA study, in
which a 25% glucose infusion was given
withinsulinandpotassium(withthepro-
tocol failing to control glycemia [25]),
improved outcome. Hyperglycemia was,
however, a marker of adverse outcome in
the latter study (26). Surgical intensive
care unit patients show reduction in in-
hospital mortality, but the data are more
controversial in medical intensive care
units. In the CLARITY-TIMI-28 study,
both high and low admission glucose
were associated with adverse outcome
(27), Fonseca pointed out, emphasizing
that “this is a very important issue...
because you are likely to get hypoglyce-
mia” with efforts to intensively treat dia-
betes. Indeed, he reviewed his studies
showingincreasedriskofischemicevents
during hypoglycemia or with rapid fall
from glucose levels 100 mg/dl. Hypo-
glycemia, Fonseca stated, “confounds the
whole business of delivering insulin to
people with CVD.”
CVD and diabetes
AnumberofstudiespresentedattheADA
Scientiﬁc Sessions gave further informa-
tion pertaining to CVD. Nishimura et al.
(abstract 163) randomized 374 type 2 di-
abetic patients to insulin aspart versus
regular insulin before meals, with 40–
42%ofpatientsalsorequiringaninterme-
diate-actingorlong-actinginsulin.Aftera
median of 4.5 years of follow-up, the cu-
mulative cardiovascular event rate was 6
vs. 11%, although CVD and overall mor-
tality did not differ. Rana et al. (abstract
79) followed 21,240 nondiabetic partici-
pants in the EPIC-Norfolk study for 11.4
years, ﬁnding that, compared with indi-
viduals with triglyceride 150 and HDL
cholesterol 50/40 mg/dl for women/
men (controlling for LDL cholesterol and
other variables), men with high triglycer-
ide alone had a 19% increase in coronary
heart disease (CHD) event rates, those
with low HDL cholesterol alone had a
65% increase in risk, and those with both
features had a 50% increase in risk. For
women, high triglyceride was associated
with a 43% increase in risk and low HDL
with a 56% increase, although those with
both abnormalities had a nonsigniﬁcant
32% increase in risk—presumably an
adverse consequence of carrying out an
excess number of statistical tests.
Yoo and Chung (abstract 608) con-
ducted a treadmill exercise electrocardio-
gram test on 114 asymptomatic type 2
diabeticpatients,withcoronaryangiogra-
phy when electrocardiographic changes
occurred during exercise. Of those with
2vs.2riskfactors,32of78vs.6of36
had CHD. Family history of CHD was as-
sociated with a 9.2-fold increase and dia-
betes duration 10 years with a 3.3-fold
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acteristics remain important determi-
nants of disease, useful in determining
which individuals should have extensive
testing. Wackers et al. (abstract 169) re-
ported 4.8-year outcome of a study ran-
domizing 1,123 type 2 diabetic patients
without CHD symptoms to screening
with stress adenosine myocardial perfu-
sion imaging or to observation; the group
had reported that 22% of those screened
had evidence of ischemia (28). Of those
screened, 15 of 558 (2.7%) had events,
while 16 of the 561 (2.9%) nonscreened
patients had myocardial infarction or car-
diac death—evidence against a policy of
aggressive screening. Those with moder-
ate/large defects on imaging and those
with ischemic ECG changes had 13.2 and
6.7% event rates, respectively, and addi-
tional predictive factors were male sex,
associated with a 3.1-fold increase; pe-
ripheral vascular disease, 3.3-fold; LDL
cholesterol, 1.2-fold per 10 mg/dl in-
crease; creatinine, 1.2-fold per 0.1 mg/dl
increase; and abnormal heart rate re-
sponse to standing, a marker of cardiac
autonomic dysfunction, 3.3-fold.
Rolin et al. (abstract 954) used the
Danish National Diabetes, Disease and
Death registries to show that incidence of
CHD decreased from 5.4 to 4.0 per 1,000
person-years among nondiabetic but
from38.4to21.7person-yearsamongdi-
abetic patients from 1995 to 2005, such
thatCHDriskamongdiabeticpatientsde-
creased from 3.8- to 2.9-fold that in the
nondiabetic age-matched population.
Ahn et al. (abstract 168) measured heart
rate variability from the expiration-to-
inspirationratioandresponsestotheVal-
salva maneuver and to standing in 1,126
diabetic patients, ﬁnding 56% with evi-
dence of cardiovascular autonomic neu-
ropathy.131hadstrokeover6–8yearsof
follow-up,withriskfactorsincludingage,
diabetes duration, hypertension, elevated
creatinine, microalbuminuria, and reti-
nopathy. Cardiac autonomic neuropathy
was independently associated with a 2.8-
fold increase in stroke risk. Eeg-Olofsson
et al. (abstract 903) analyzed the relation-
ship between weight status and CVD in
10,896 Swedish type 2 diabetic patients
followed for 6 years, ﬁnding that over-
weightorobesitywereassociatedwith39,
44, and 41% increases in risk of CHD,
stroke, and mortality, respectively, with
somewhat higher rates after adjustment
forage,sex,diabetesduration,andsmok-
ing. Arsenault et al. (abstract 904) fol-
lowed 21,729 individuals for up to 11
years, with 2,191 developing CHD. Physi-
cal inactivity was associated with a 30% in-
crease in CHD. Increased BMI and, to a
greaterextent,waistcircumferencewereas-
sociated with 50–100% increases in
CHD, with the combination of physical in-
activity and obesity by either measure asso-
ciated with 3- to 11-fold increases in CHD.
Polak et al. (abstract 261) analyzed
carotid intima-media thickness in the Ep-
idemiology of Diabetes Interventions and
Complications follow-up of the DCCT,
ﬁnding that although the rate of progres-
sion in former intensively treated patients
was lower from 1 to 6 years after the con-
clusion of the DCCT, there was no differ-
ence in rate of progression between the
former control and intensive treatment
groups from 6 to 12 years. Similarly, Al-
bers et al. (abstract 236) reported on a
14-year post-DCCT follow-up of 908
type 1 diabetic patients in which an in-
creasewasfoundintheprevalenceofneu-
ropathy from 9 to 24% among those
formerly receiving intensive and from 17
to 33% among those formerly receiving
conventional insulin treatment; the re-
duction in magnitude of difference be-
tween the groups suggests resumption of
neuropathy development after discontin-
uation of intensive treatment. Rutledge et
al. (abstract 311) reported on a 11–12
year post-DCCT follow-up of albumin-
uria (40 mg/24 h) development that
foundcumulativeincidenceof18vs.25%
in the former intensive glycemic treat-
ment group versus the control group, al-
though analysis of the development
pattern suggested that the protective ben-
eﬁt was limited to the ﬁrst 7–8 years after
the conclusion of the DCCT. The ”meta-
bolic memory” phenomenon of beneﬁt
from early intervention may then be of
limited duration in type 1 diabetes.
Neuropathy
Kulzer et al. (abstract 1853) studied 211
diabetic patients and found neuropathy
in 39%, of whom 48% had evidence of
depression, which emerged as a frequent
comorbid condition with painful neurop-
athy.Flottemeschetal.(abstract361)fol-
lowed 14,144 adult diabetic patients of
whom 2,179 had a diagnosis of and/or
were treated for depression, the latter
group with lower rates of A1C and LDL
cholesterol monitoring. Selvarajah et al.
(abstract 1864) analyzed the effect of de-
pression on the response of 28 diabetic
individuals with painful neuropathy to
sativex, a potential therapeutic agent,
compared with placebo. No treatment ef-
fect was shown, but depressed patients
improved signiﬁcantly whether receiving
active treatment or placebo, suggesting
that this is an important confounder of
clinical trials in painful diabetic neuropa-
thy. Similarly, Echeverry et al. (abstract
115) treated 56 depressed diabetic pa-
tients with 50–100 mg sertraline daily
versus placebo for 6 months and found
signiﬁcant improvement in A1C and in
qualityoflifescorebothwithandwithout
pharmacologic antidepressant treatment,
suggesting a beneﬁt of the greater degree
of health care provider interaction.
Anumberofnewlydiscoveredfactors
may play roles in the development of di-
abetic neuropathy. Pitocco et al. (abstract
157) studied a polymorphism in osteo-
protegerin, an important regulator of
bone remodeling, and found patients
with Charcot neuroarthropathy to have a
2.4-foldgreaterlikelihoodofhavingtheG
allele and a 40% reduction in presence of
the C allele, while there was no associa-
tion with diabestic neuropathy alone.
Carvalho et al. (abstract 242) studied an-
imal wound healing models not express-
ing the neurokinin-1 receptor, the site of
action of substance P, or treated with the
receptor antagonist CJ 12,255, showing
reduction in wound healing in nondia-
betic animals but no effect in diabetic
mice,suggestingthistobeapotentialarea
for pharmacologic treatment.
Chen et al. (abstract 1942) adminis-
tered autologous bone marrow mesenchy-
mal stem cells by multiple intramuscular
and subcutaneous injections into lower
limbs with an ankle-brachial index of
0.90andfoundareductioninrestpainof
40%, with a 140% increase in pain-free
walking distance; control patients had a
10% reduction and 10% increase in the re-
spective measures. Fifteen of 18 foot ulcers
healed among those receiving transplants,
but 9 of 20 ulcers healed among controls,
indicating this could potentially be a useful
approach. Kipnes et al. (abstract 235) ad-
ministered vascular endothelial growth fac-
tor zinc ﬁnger protein activator SB-509 or
placebointramuscularlyto24patientswith
diabetic neuropathy and found improve-
ment in motor and sensory nerve conduc-
tion velocity and in vibration sensation at
6 months, suggesting potential nerve
regeneration.
Jeffcoate et al. (abstract 158) per-
formed a randomized controlled trial of
threedressingproductsusedatleasttwice
weekly, a simple knitted viscose primary
dressing (N-A), an antiseptic preparation
(Inadine) and sodium carboxymethylcel-
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with foot ulcers also receiving standard
care with regular surveillance, sharp de-
bridement, and appropriate off-loading.
At 24 weeks, 39, 44, and 45% of the re-
spective groups had healed, with the
authors concluding that there was no dif-
ference in the effectiveness of the three
dressings. Bowling et al. (abstract 1093)
compared the Visitrak digital planimetry
system to use of a paper tape measure to
ascertain wound circumference; the latter
was more accurate for wounds 2.5 cm
2
and considerably less expensive, with the
two approaches otherwise quite similar,
suggesting the “low tech” approach to be
preferable. LeMaster et al. (abstract 160)
randomized 79 patients with diabetic
neuropathytocontrolorwalkingexercise
groups, the latter using pedometers, and
both groups were given diabetic foot care
education, regular foot care, and eight
sessions with a physical therapist. There
was one plantar ulcer in each group at 6
months and ﬁve vs. one ulcer at 12
months, suggesting walking to be poten-
tiallybeneﬁcialinthesepatients.Gameetal.
(abstract 1094) screened 111 foot ulcers
from 93 consecutive diabetic patients in
2007andfoundmethicillin-resistantStaph-
ylococcus aureus in 15%, increased from
10%in2002;thatmostofthepatientslived
in the community rather than being hospi-
talized and with prolonged use of broad-
spectrum antibiotics also no longer a risk
factor suggests that screening should be
performed more widely for this organism.
Dellon et al. (abstract 1090) reported
on a prospective (but neither randomized
nor controlled) follow-up of 618 diabetic
individuals with a positive Tinel sign over
the tibial nerve in the tarsal tunnel and
painful neuropathy symptoms undergo-
ing decompression surgery, reporting
thatat1-yearfollow-upamong146ofthe
patients, pain was reduced on average
from 8.5 to 1.5 on a 10-point scale, with
improvement in 2-point discrimination
in somewhat under one-quarter of the
population and foot ulceration in fewer
than 1%. A controlled study would be re-
quiredtoascertainwhethertheprocedure
is actually of beneﬁt. Similarly, Kempf et
al. (abstract 489) treated 167 patients with
painful diabetic neuropathy with a high-
frequency external muscle stimulation de-
vice, reporting reduction in a variety of
symptoms,againwithoutacontrolgroupto
establish the validity of the response.
Ejskjaer et al. (abstract 298) adminis-
tered the ghrelin agonist TZP-101 to 10
patients with severe diabetic gastroparesis,
showing improved gastric emptying for liq-
uidsandsolids,withmeal-relatedsymptom
score improved in ﬁve of eight patients
studied, on average by 24%, and with 37%
reduction in postprandial fullness.
Retinopathy
Rosenstock et al. randomized 1,017 type
2 diabetic patients to glargine daily vs.
NPH twice daily plus regular insulin as
needed for 5 years, with baseline A1C 8.4
vs. 8.3% and a signiﬁcant 0.2% greater
reduction in A1C with NPH but trends to
less weight gain and hypoglycemia with
glargine. Diabetic retinopathy was
present at baseline in 16 vs. 12%, with
noninferiority of glargine, as 14 vs. 16%
showed retinopathy progression by 3
steps after 5 years. Thomas et al. (abstract
809) found retinopathy using a nonmyd-
riatic camera in 15% of 336 newly diag-
nosed type 2 diabetic patients, ﬁnding
similarage,fastingglucose,A1C,andfast-
ing and postprandial insulin but a 2-h
postprandialglucoseof283vs.261mg/dl
in those with versus without retinopathy,
respectively. Those with sight-threaten-
ing retinopathy or maculopathy had
higher systolic blood pressure.
Sun et al. (abstract 816) studied type
1 diabetic individuals with disease dura-
tion 50 years, ﬁnding that of 46 with a
mean 24 years of follow-up, those with
greater progression of retinopathy had a
higher 7-year mean A1C and the serum
advanced glycation end product carboxy-
ethyl-lysine. Of 287 studied at one time
point, proliferative retinopathy again cor-
related with this measure, but not with
A1C, and there was no association of
retinopathy with elevations in carboxy-
methyl-lysine,furosine,or2-aminoadipic
acid. Wu et al. (abstract 54) analyzed ret-
inal sections from nondiabetic individu-
als and from diabetic patients without
retinopathy, with moderate nonprolifera-
tive retinopathy, or with proliferative di-
abetic retinopathy. Macrophages partially
colocalizedwithapoliproteinB100insec-
tions of patients with proliferative reti-
nopathy and with intraretinal oxidized
LDL cholesterol in all three diabetic
groups but not in the nondiabetic group,
correlating with retinopathy severity.
Glucose- and oxidative stress–modiﬁed
LDL cholesterol might cause retinopathy,
perhaps interfering with retinal capillary
pericytes. Zhang et al. (abstract 50) re-
ported that human retinal pericytes ex-
posed to heavily oxidized glycated LDL
cholesterol showed increased monocyte
chemoattractant protein (MCP)-1 pro-
duction, with the antiangiogenic pigment
epithelium-derived factor (PEDF) reduc-
inglevelsoftheMCP-1andperoxynitrite,
reﬂecting an effect on oxidative stress.
Wangetal.(abstract715)fromthisgroup
reported similar suppression of renal
MCP-1 and other inﬂammatory factors
with PEDF overexpression. Villacampa et
al. (abstract 49) studied IGF-I transgenic
diabetic mice, which develop features of
nonproliferative retinopathy; overexpres-
sion of PEDF reduced retinal neovascu-
larizationandexpressionofinﬂammatory
molecules.
Geraldes et al. (abstract 52) showed
that exposure of isolated bovine retinal
pericytes to high glucose increased peri-
cyte apoptosis and reduced response to
platelet-derived growth factor (PDGF) by
a mechanism involving protein kinase C
and p38 mitogen-activated protein ki-
nase, with models not expressing active
forms of these enzymes showing resis-
tance to pericyte loss with hyperglycemia
and increased PDGF response, which
might offer a mechanism of the long-
term adverse effect of hyperglycemia.
Obrosova et al. (abstract 51) found
poly(ADP-ribose) polymerase (PARP)
expressioninthelensandretina.Cataract
occurred in 94% of streptozotocin-
diabeticratsbutin69and50%ofdiabetic
animals administered two different PARP
inhibitors, which also reduced retinal ox-
idative-nitrosative stress and glial activa-
tion. Behl et al. (abstract 48) found that
rat microvascular endothelia cells incu-
bated in high glucose had increased apo-
ptosis, which decreased 60–70% by
inhibiting transcription of the forkhead
factor FOXO1 either with small interfer-
ing RNA for FOXO1 or by inhibiting tu-
mor necrosis factor-; translocation of
FOXO1 to the nucleus was ﬁve times
greater in retinal digests from animals
with diabetes for 6 months. Retinal cell
apoptosis and pericyte ghost formation,
increased by diabetes, were reduced 75%
with intravitreal FOXO1-speciﬁc siRNA.
Roy et al. (abstract 47) gave three intrav-
itreal injections of siRNA targeted to ﬁ-
bronectin, which is overexpressed in
diabeticretina,overa4.5monthperiodto
streptozotocin-diabetic rats. Retinal ﬁ-
bronectin expression and retinal capillary
basement membrane thickening were
both reduced 1.5 months later.
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